Navigation Links
New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
Date:9/25/2008

- Transdermal Estrogen Analyses Continue to Show Benefits of Hormone

Therapy Use in Menopausal Women -

MAPLE GROVE, Minn., Sept. 25 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced that clinical abstracts featuring Divigel(R) (estradiol gel) 0.1% were presented at the North American Menopause Society's 19th Annual Meeting in Orlando, Florida. Divigel(R) is a transdermal estrogen therapy that was approved by the FDA in June 2007. It offers the lowest approved dose of estradiol gel for the treatment of moderate to severe hot flashes associated with menopause.

"These analyses indicate that Divigel(R) (estradiol gel) 0.1% is a valuable alternative for certain postmenopausal women with moderate to severe hot flashes," said Ronald Ackerman, MD, FACOG, CEO and principal investigator, Comprehensive Clinical Trials. "Analyses like these are crucial to further educate women about the benefits of hormone therapy for the management of hot flashes."

The first abstract presented at the meeting was a post-hoc analysis of 488 patients from a Phase III clinical trial to determine the effect of uterine status (intact, absent) plus Divigel(R) (1.0 g/day, 0.5 g/day, 0.25 g/day) compared to placebo on the change from baseline to week 12 in the frequency and severity of hot flashes. This study revealed that Divigel(R) is an effective treatment for the relief of moderate to severe hot flashes in postmenopausal women regardless of ovarian or uterine status.

The second abstract used the same patient population to evaluate the effect of age (<50 years, 50-59 years, greater than or equal to 60 years) and age plus Divigel(R) (1.0 g/day, 0.5 g/day, 0.25 g/day) combined compared to placebo on the change from baseline to week 12 in frequency and severity of moderate to severe hot flashes. This study revealed that Divigel(R) is an effective treatment for relief of hot flashes in postmenopausal women of any age; however, the e
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  TissueGene, Inc. a clinical-stage biopharmaceutical ... the field of cell therapy, today announced the ... of Chief Operating Officer.  Mr. Newman was most ... Clinical Operations at ZIOPHARM Oncology, a ... gene expression, control and cell technologies in the ...
(Date:4/21/2015)... and PARIS and BURLINGTON, N.C. , ... (NYSE: DGX ), the world,s leading provider ... National Institute of Health and Medical Research institution, ... they co-founded to provide scientists and laboratory organizations ... and BRCA2 genetic data. The program,s goal is ...
(Date:4/21/2015)... April 21, 2015 /PRNewswire/ -- Mindray Medical International Limited ("Mindray", ... marketer of medical devices worldwide, today announced that it ... ended Mar 31, 2015 after the U.S. market closes ... earnings conference call at 8:00 AM on May 12, ... 2015 Beijing/Hong Kong Time). Dial-in details ...
Breaking Medicine Technology:TissueGene, Inc. Hires Robert Newman as Chief Operating Officer 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 3Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 4Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 5Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 6Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 7Mindray to Report 2015 First Quarter Financial Results on May 11, 2015 2
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 What ... Jessica Parker, Tom Ford and Ted Turner have in common? ... of the 50 Most Powerful Americans 50+. In a 16-page ... Chief of more than 50 magazines and 25 websites, along ... on the power they wield through the unique lens of ...
(Date:4/21/2015)... 21, 2015 Zane Benefits, a software ... its CEO Rick Lindquist has been selected as one ... According to Rick Lindquist, “There is a massive shift ... Benefits’ small business solutions are at its forefront. Our ... Employee Benefit Adviser’s Rising Stars.” , According to the ...
(Date:4/21/2015)... Let's face it; a lot of skin ... and complex routines for hundreds of dollars. Block ... gimmicks, as the sun is the leading cause of skin ... more than just daily sun protection; it is also about ... new Purifying Facial Cleanser and Revitalizing Night ...
(Date:4/21/2015)... April 21, 2015 Quark Software ... a new knowledge management solution that enables large ... of policies and procedures. With Quark Procedure Management, ... content that is easy to save, search and ... to risk and compliance issues. Examples of policies ...
(Date:4/21/2015)... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... report results for the first quarter of 2015 on ... market. , The Company will host a conference ... release at 4:30 PM ET. Investors interested in ... at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. ...
Breaking Medicine News(10 mins):Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 2Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 3Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 4Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 3Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015 2
... Fla. October 24, 2011 Patients in the United ... able to benefit from a new treatment that is already ... The treatment, called collagen crosslinking, improved vision in almost 70 ... clinical trial in Milan, Italy. The treatment is in clinical ...
... Heavy alcohol consumption may be linked to a ... and increased consumption of black tea and fruit are ... three separate studies presented at CHEST 2011, the 77th ... (ACCP), heavy alcohol consumption was related to increased risk ...
... Lung Cancer Mortality Rates , (#1111771, Tuesday, October ... has one of the highest mortality rates in the ... on data from the National Cancer Institute Surveillance, Epidemiology, ... Regional Medical Center in Flint, Michigan and the Mayo ...
... training on a take-home simulator do a better job once ... told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart ... Dr. Lam and a multidisciplinary surgical team developed a kit ... be taken home by trainees to practice a highly technical ...
... reconstruction with tissue from their own abdomen experience significant ... as three weeks after surgery. That is one of ... in Cancer , a peer-reviewed journal of the ... to breast cancer survivors who are contemplating these types ...
... -- While there are challenges, Halloween can still be fun ... enjoy Halloween and enjoy some of the sweets the holiday ... and senior scientist at the University of Alabama at Birmingham ... "We give parents and kids three options and let them ...
Cached Medicine News:Health News:Vitamin B-based treatment for corneal disease may offer some patients a permanent solution 2Health News:Heavy alcohol consumption linked to lung cancer 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 3Health News:Heart surgeons-in-training benefit from hands-on homework 2Health News:Advanced post-mastectomy breast reconstruction improves women's psychosocial and sexual well-being 2Health News:Healthy Halloween Advice for Children With Diabetes 2
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
Stent delivery with extra rail support...
Medicine Products: